GSM & Vaginal Estrogen Navigator

Genitourinary syndrome of menopause is common, progressive, treatable — and almost never treated.

Genitourinary syndrome of menopause (GSM) is the collection of vulvar, vaginal, sexual, and urinary symptoms caused by falling estrogen. Unlike hot flashes, it does not resolve on its own. It progresses. It affects roughly 27% to 84% of postmenopausal women.

Low-dose vaginal estrogen relieves it in most women, is barely absorbed into the bloodstream, and costs very little. Almost nobody gets it.

9.0%

of 1,838,732 Medicare women with a GSM diagnosis ever filled a vaginal estrogen prescription

Gallo 2025

1.4%

filled it when recurrent UTI was their only recorded GSM symptom

Gallo 2025

15 mo

median time from GSM diagnosis to filling a prescription

Gallo 2025

Black beneficiaries had 40% lower adjusted odds of filling a prescription than non-Hispanic White beneficiaries (aOR 0.60; 95% CI 0.59–0.62). Vaginal creams accounted for 90.3% of all fills.

What this tool does

It walks through the symptoms of GSM, prompts the differential diagnoses that GSM is mistaken for, and sets out what the evidence supports for treatment — including the specific situations where the answer is examine first or decide with the oncologist, not prescribe.

What this tool does not do

It does not diagnose. GSM is a clinical diagnosis that requires history and examination.
It does not calculate a risk score. No validated GSM risk model exists, and inventing one would be worse than having none.
It does not replace clinical judgment, and it is not a substitute for a conversation with your clinician.

Every number displayed traces to a specific publication. The full source list, with annotations, is on the evidence page.

Step 1 of 2

Symptoms and history

Nothing you enter leaves your browser. There is no server.

1. Which symptoms are present?

Select all that apply. Categories follow the NAMS symptom definitions used in the Medicare analysis.

VulvovaginalDryness, burning, irritation, itching SexualPain with intercourse, bleeding after intercourse, loss of lubrication BladderUrinary urgency, frequency UrethralPainful urination (dysuria) Recurrent urinary tract infections3 or more separate UTIs, each at least 30 days apart, in one year

2. How bothersome are the symptoms?

This matters: with one mild symptom, a non-hormonal moisturizer performs about as well as vaginal estrogen (Rahn 2014).

3. Are any of these present?

These point away from uncomplicated GSM. They call for examination — and sometimes biopsy — before any estrogen is prescribed. Clinical differential prompts; not derived from a cited dataset.

Any vaginal bleeding after menopauseRequires evaluation for endometrial pathology first White, thickened, or crinkled vulvar skin; loss of the labia minora; fissuresSuggests lichen sclerosus — needs examination, often biopsy A lump, ulcer, or persistent sore that does not healBiopsy to exclude vulvar intraepithelial neoplasia or malignancy Sharp, well-localized pain at the vaginal opening with normal-looking tissueSuggests vulvodynia or a hypertonic pelvic floor, not atrophy Abnormal discharge, odor, or a new rash after a new productSuggests infection or contact dermatitis None of these

4. Is the uterus present?

5. History of breast cancer?

This changes the conversation, not automatically the answer.

6. History of endometrial cancer?

Step 2 of 2

What the evidence supports

The treatment gap, for this symptom pattern

Formulations

Low-dose vaginal estrogen is defined pharmacologically as the 7.5 µg/24 h ring and the 10 µg tablet; these raise plasma estradiol during long-term use but not above the postmenopausal range of ≤20 pg/mL (Santen 2015). Intermediate and high doses reach or exceed that range. Doses below are the FDA-labeled regimens for each product; the evidence column reports what has been studied.

Option	Typical labeled use	What the evidence shows
Lubricants and moisturizers	As needed / 2–3× weekly	Equivalent to vaginal estrogen when there is one mild symptom; inferior when two or more symptoms are present (Rahn 2014)
Estradiol vaginal cream	Per labeling, usually nightly to start, then twice weekly	Effective for dryness, dyspareunia, urgency, frequency, incontinence; 90.3% of all US fills (Rahn 2014; Gallo 2025)
Estradiol 10 µg vaginal insert	Nightly ×2 weeks, then twice weekly	Low-dose; no increase in endometrial hyperplasia or carcinoma over 52 weeks in 386 evaluable biopsies (Simon 2010)
Estradiol vaginal ring (7.5 µg/24 h)	One ring, replaced every 90 days	Prolongs time to next UTI; 45% vs 20% remained UTI-free at 36 weeks (Eriksen 1999, RCT)
Vaginal DHEA (prasterone)	One insert nightly	Effective for moderate–severe GSM; long-term endometrial safety data lacking (NAMS 2020)
Ospemifene	Oral, daily	Effective for moderate–severe GSM; long-term endometrial safety data lacking (NAMS 2020)
Energy-based devices (vaginal laser)	—	Insufficient placebo-controlled trials to draw conclusions on efficacy or safety; NAMS makes no treatment recommendation (NAMS 2020)

What to expect

Roughly 60% to 80% of women report meaningful improvement in symptom severity (NAMS 2020; Crandall 2023).
Most trials ran only 12 weeks. Do not judge failure before then.
GSM is progressive and does not remit. Treatment is maintenance, not a course.
Safety data beyond one year of use remain limited. That is a real gap, and it should be stated rather than hidden.
No randomized trial has been powered to test whether vaginal estrogen causes heart disease, cancer, or blood clots. The reassurance is observational, not randomized.

Evidence & citations

Every number in this tool traces to one of these publications.

Levels of evidence used here

RCTSystematic reviewObservationalGuideline / position statement

ObservationalGallo K, Zhang CA, Burton C, Kamdar N, Enemchukwu EA. Vaginal estrogen utilization among Medicare beneficiaries with genitourinary syndrome of menopause. JAMA Netw Open. 2025;8(12):e2549822. doi:10.1001/jamanetworkopen.2025.49822 Primary source for the treatment gap. Retrospective cohort, 20% Medicare sample, 2006–2018; 1,838,732 women aged ≥66 with a GSM-related diagnosis. 165,530 (9.0%) filled a vaginal estrogen prescription, at a median of 15 months. Supplies every symptom-group fill rate shown in this tool.
Systematic reviewRahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-56. doi:10.1097/AOG.0000000000000526 44 eligible studies. Vaginal estrogens improved dryness, dyspareunia, urgency, frequency, stress and urgency incontinence, and reduced UTI rates. Source of the finding that women with one or minor symptoms do as well on a non-hormonal moisturizer, while those with two or more symptoms do substantially better on vaginal estrogen.
RCTRaz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-6. doi:10.1056/NEJM199309093291102 93 postmenopausal women, randomized, double-blind, placebo-controlled. UTI incidence 0.5 vs 5.9 episodes per patient-year (P<0.001). Vaginal pH fell from 5.5 to 3.8; lactobacilli returned in 61% of treated women and none of the placebo group.
RCTEriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072-9. doi:10.1016/S0002-9378(99)70597-1 108 women randomized. At 36 weeks, the cumulative likelihood of remaining free of UTI was approximately 45% with the ring versus approximately 20% with no estrogen (P=0.008). Open-label, untreated control group.
ObservationalCrandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20. doi:10.1097/GME.0000000000000956 45,663 women, median follow-up 7.2 years, none using systemic estrogen. Among women with a uterus, no significant difference in stroke, invasive breast cancer, colorectal cancer, endometrial cancer, or pulmonary embolism/DVT between users and non-users; risks of coronary heart disease, fracture, all-cause mortality, and the global index event were lower in users (GIE adjusted HR 0.68; 95% CI 0.55–0.86). Observational — residual confounding by healthy-user bias cannot be excluded.
ObservationalSanten RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121-34. doi:10.3109/13697137.2014.947254 Pharmacokinetic review. Low-dose vaginal estrogen (7.5 µg ring, 10 µg tablet) raises plasma estradiol during chronic use but not above the postmenopausal range of ≤20 pg/mL. Intermediate doses approach or exceed it; high doses reach premenopausal levels. Low-dose regimens limit but do not eliminate systemic absorption.
ObservationalSimon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010;116(4):876-83. doi:10.1097/AOG.0b013e3181f386bb 541 women on 10 µg estradiol vaginal tablets for 52 weeks; 443 biopsied at week 52. 85.6% atrophic endometrium. Two events of hyperplasia or carcinoma among 386 evaluable biopsies (0.52% per year), against a reported background rate of 0% to 1%. Supports use without a progestogen; the trials ran one year, not longer.
ObservationalCold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347-54. doi:10.1093/jnci/djac112 8,461 postmenopausal women with early-stage ER-positive breast cancer; 1,957 used vaginal estrogen. Adjusted relative risk of recurrence 1.08 (95% CI 0.89–1.32) overall — but 1.39 (95% CI 1.04–1.85) in the subgroup receiving adjuvant aromatase inhibitors. Overall mortality adjusted HR 0.78 (0.71–0.87). This single subgroup finding is the reason the aromatase-inhibitor pathway in this tool differs from the others.
ObservationalMcVicker L, Labeit AM, Coupland CAC, Hicks B, Hughes C, McMenamin Ú, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-8. doi:10.1001/jamaoncol.2023.4508 49,237 women with breast cancer in Scottish and Welsh cohorts, 5,795 breast-cancer deaths. 5% used vaginal estrogen. No evidence of higher breast-cancer-specific mortality in users versus HRT non-users (pooled adjusted HR 0.77; 95% CI 0.63–0.94).
ObservationalAgrawal P, Singh SM, Able C, Dumas K, Kohn J, Kohn TP, et al. Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. Obstet Gynecol. 2023;142(3):660-8. doi:10.1097/AOG.0000000000005294 42,113 women with GSM after breast cancer; 5.0% received vaginal estrogen. Recurrence risk comparable in users and non-users for any receptor status (RR 1.03; 95% CI 0.91–1.18) and for ER-positive disease (RR 0.94; 95% CI 0.77–1.15).
Position statementThe NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. doi:10.1097/GME.0000000000001609 GSM affects approximately 27% to 84% of postmenopausal women and is likely underdiagnosed and undertreated. Low-dose vaginal estrogen, vaginal DHEA, systemic estrogen, and ospemifene are effective for moderate to severe GSM. Long-term endometrial safety data for vaginal estrogen, DHEA, and ospemifene are lacking. Evidence is insufficient to recommend energy-based (laser) therapies.
GuidelineKaufman MR, Ackerman AL, Amin KA, Coffey M, Danan E, Faubion SS, et al. The AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause. J Urol. 2025;214(3):242-50. doi:10.1097/JU.0000000000004589 Joint urology, female pelvic medicine, and urogynecology guideline. Notes that no consensus exists on the number or type of symptoms required to diagnose GSM, and that GSM urinary symptoms overlap with overactive bladder and other urologic conditions.
Systematic reviewMili N, Paschou SA, Armeni A, Georgopoulos N, Goulis DG, Lambrinoudaki I. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706-16. doi:10.1097/GME.0000000000001752 27 studies. GSM symptom prevalence ranged from 13% to 87%. Low-dose vaginal estrogen was used by only 4.8% to 35.0% of symptomatic women. Unlike vasomotor symptoms, GSM symptoms persist throughout life.
ReviewCrandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405-20. doi:10.1001/jama.2022.24140 Narrative review supporting the 60% to 80% symptom-improvement figure for low-dose vaginal estrogen.
ObservationalYang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum. 2024;5(9):e243128. doi:10.1001/jamahealthforum.2024.3128 NHANES, 13,048 postmenopausal women. Menopausal hormone therapy use fell from 26.9% (1999–2000) to 4.7% (2017–March 2020). Context for the undertreatment of menopause generally.

What is not established

No randomized trial has been powered to determine whether vaginal estrogen causes cardiovascular disease, cancer, or venous thromboembolism. Reported adverse events in trials are local, such as discharge. Most trials lasted 12 weeks; safety data beyond one year are limited. The breast cancer evidence is entirely observational. There is one randomized trial of oral estrogen after stage I–II endometrial cancer, not of vaginal estrogen. Anyone who tells you the safety question is closed is telling you something the literature does not say.